RyanJSullivanMD

PubMed

• Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: An international multicenter cohort study.
  Xue Bai, Aleigha R Lawless, Juliane A Czapla, Stefanie C Gerstberger, Benjamin C Park, Seungyeon Jung, Rebecca Johnson, Naoya Yamazaki, Dai Ogata, Yoshiyasu Umeda, Cai...> ;JAAD International. 2024 Jun 1
• Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.
  Steven T Chen, Yevgeniy R Semenov, Allireza Alloo, Daniel Q Bach, Allison Betof Warner, Amina Bougrine, Leeann Burton, Laura C Cappelli, Mariana Castells, Justine Cohe...> ;Journal for Immunotherapy of Cancer. 2024 Apr 10
• Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.
  Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, Jennifer R Wortman, Elizabeth M Burton, Farah A Alayli, Christopher P Loo, Shikha Gautam, Ashish Damania, Ju...> ;Cancer Discovery. 2024 Apr 4
• What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?
  Matthew J Hadfield, Ryan J Sullivan> ;Cancer Journal. 2024 Mar 25
• Phase 1/2 study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors.
  Corcoran, R., Do, K., Kim, J., Cleary, J., Parikh, A., Yeku, O., Xiong, N., Weekes, C., Veneris, J., Ahronian, L., Mauri, G., Tian, J., Norden, B., Michel, A., Van Sev...> ;Clinical Cancer Research. 2024 Mar 8
• Acute and chronic kidney function decline in patients receiving BRAF/MEK inhibitors for melanoma.
  Zhao, S., Strohbehn, I., Strohbehn, S., Katz-Agranov, N., Mistry, K., Wang, Q., Hanna, P., Sullivan, R., Sise, M.> ;Nephrology, Dialysis, Transplantation. 2024 Feb 22
• Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
  Or-Yam Revach, Angelina M Cicerchia, Ofir Shorer, Boryana Petrova, Seth Anderson, Joshua Park, Lee Chen, Arnav Mehta, Samuel J Wright, Niamh McNamee, Aya Tal-Mason, Gi...> ;Biorxiv. 2024 Mar 26
• 3 citations
  Multicenter Evaluation of Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma and Review of Recent Literature.
  Smart, A., Giobbie-Hurder, A., Desai, V., Lukens, J., Taunk, N., Sullivan, R., Mooradian, M., Hsu, C., Buchbinder, E., Schoenfeld, J., Xing, J.> ;Advances in Radiation Oncology. 2024 Jan 1
• Detection of Copy-Number Variation in Circulating Cell-Free DNA in Patients With Uveal Melanoma.
  Takuto Sato, Kamaneh Montazeri, Evangelos S Gragoudas, Anne Marie Lane, Mary Beth Aronow, Justine V Cohen, Genevieve M Boland, Eric Banks, Christopher Kachulis, Mark F...> ;JCO Precision Oncology. 2024 Jan 1
• Tofacitinib is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis.
  Wang, M., Montazeri, K., Schaefer, E., Sullivan, R., Dougan, M., Reynolds, K.> ;Clinical Gastroenterology and Hepatology. 2023 Dec 22
• Immune Responses in Checkpoint Myocarditis Across Heart, Blood, and Tumor.
  Steven M Blum, Daniel A Zlotoff, Neal P Smith, Isabela J Kernin, Swetha Ramesh, Leyre Zubiri, Joshua Caplin, Nandini Samanta, Sidney C Martin, Alice Tirard, Pritha Sen...> ;Biorxiv. 2023 Nov 29
• Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.
  Paul B Chapman, Mark Klang, Michael A Postow, Ryan J Sullivan, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K Callahan, Bin Zheng, Shoushtari, A., Zippin, J., Wo...> ;Cancer Research Communications. 2023 Dec 4
• 2 citations
  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
  Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, Diwakar Davar, Geoffrey T Gibney, Omid Hamid, Tina J Hieken, Benjamin Izar, Douglas B Johnson, Rajan P Kulk...> ;Journal for Immunotherapy of Cancer. 2023 Oct 1
• Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
  Rachel S Goodman, Lorenza Di Guardo, Andrea Maurichi, Brendan Kirwin, Adnan Khattak, Vito Vanella, Joanna Lee, Aleigha Lawless, Juliane Czapla, Andrea Spagnoletti, Mar...> ;European Journal of Cancer. 2023 Nov 1
• Immunotherapy in Melanoma: Recent Advancements and Future Directions.
  Meghan J Mooradian, Ryan J Sullivan> ;Cancers. 2023 Aug 19
• To Inhibit or Not to Inhibit MEK With BRAF Inhibitors: Is That the Question?
  Ryan J Sullivan> ;Journal of Clinical Oncology. 2023 Oct 10
• 7 citations
  Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses.
  Steven M Blum, Sherin J Rouhani, Ryan J Sullivan> ;Immunological Reviews. 2023 Sep 1
• 8 citations
  Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
  Rachel S Goodman, Aleigha Lawless, Rachel Woodford, Faisal Fa'ak, Asha Tipirneni, J Randall Patrinely, Hui Ling Yeoh, Suthee Rapisuwon, Andrew Haydon, Iman Osman, Jani...> ;JAMA Network Open. 2023 Aug 1
• 2 citations
  Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
  Paolo A Ascierto, Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua D Brody, Leisha A Emens, Robert L Ferris, Silvia C Formenti, Omid Hamid, Douglas B Johnson, ...> ;Journal of Translational Medicine. 2023 Jul 20
• The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.
  Meghan J Mooradian, Ryan J Sullivan> ;Cancer. 2023 Jul 15
• 2 citations
  Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
  Hong, D., Postow, M., Chmielowski, B., Sullivan, R., Patnaik, A., Cohen, E., Shapiro, G., Steuer, C., Gutierrez, M., Yeckes-Rodin, H., Ilaria, R., O'Connell, B., Peng,...> ;Clinical Cancer Research. 2023 Jun 13
• 5 citations
  Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
  Priscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, Eudocia Q Lee, Nancy U Lin, Beth Overmoyer, Patrick Y Wen, Lakshmi Nayak, Justine V Cohen, Jorg Dietrich, A...> ;Nature Medicine. 2023 Jul 1
• 4 citations
  Toxicities associated with immune checkpoint inhibitors: a systematic study.
  Xiangyi Kong, Li Chen, Zhaohui Su, Ryan J Sullivan, Steven M Blum, Zhihong Qi, Yulu Liu, Yujia Huo, Yi Fang, Lin Zhang, Jidong Gao, Jing Wang> ;International Journal of Surgery. 2023 Jun 1
• Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.
  Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc...> ;Journal for Immunotherapy of Cancer. 2023 May 1
• The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022.
  Paolo A Ascierto, Renier Brentjens, Samir N Khleif, Kunle Odunsi, Katayoun Rezvani, Marco Ruella, Ryan J Sullivan, Bernard A Fox, Igor Puzanov> ;Journal of Translational Medicine. 2023 Apr 22
• Join now to see all

Journal Articles

• Publisher Correction: Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
  Genevieve Boland, Ryan J Sullivan, Keith Flaherty, Nature
• Robust Prediction of Response to Immune Checkpoint Blockade Therapy in Metastatic Melanoma  
  Ryan J Sullivan, Genevieve Boland, Keith Flaherty, Nature

Lectures

• Debate: Immunotherapy Targeted Therapy Versus Immunotherapy Sequencing — Immunotherapy Sequencing... 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
• Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Other

• Forestalling BRAF-Inhibitor Resistance in a Shocking Way 
  Ryan Sullivan, MD, Clinical Cancer Research
  https://www.doximity.com/articles/250420a4-97de-460d-87c1-5ef5e3415ddc
  UpToDate, Wolters Kluwer Health - 2013-04-10